Fc receptor binding proteins

Abstract

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

1 - 96 : (canceled) 
     
     
         97 : A method for reducing the binding of IgG to FcRn in an individual comprising:
 providing an antibody or a fragment thereof which binds to human FcRn, is generated against the heavy chain of human FcRn or a fragment thereof, is a non-competitive inhibitor of IgG binding to human FcRn and does not bind β2-microglobulin; and   administering the antibody or the fragment thereof to an individual in an amount sufficient to reduce the binding of IgG to FcRn in the individual.   
     
     
         98 - 110 : (canceled) 
     
     
         111 : The method of  claim 97 , wherein the individual has an autoimmune or alloimmune disease. 
     
     
         112 : The method of  claim 97 , wherein the individual is an organ transplant recipient. 
     
     
         113 : The method of  claim 97 , wherein the individual has been administered a therapeutic antibody. 
     
     
         114 : The method of  claim 97 , wherein the autoimmune disease is immune thrombocytopenia. 
     
     
         115 : The method of  claim 97 , wherein the autoimmune disease is immune pemphigus. 
     
     
         116 : The method of  claim 97 , wherein the individual is a human. 
     
     
         117 : The method of  claim 97 , wherein the antibody is administered at a dosage of 1 mg/kg to 2 g/kg. 
     
     
         118 : The method of  claim 97 , wherein the antibody is administered at a dosage of 1 mg/kg to 200 mg/kg. 
     
     
         119 : The method of  claim 97 , wherein the antibody comprises a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence; and wherein
 the HC comprises:
 a HC CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO:144) or VYAMG (SEQ ID NO:156), 
 a HC CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO:145) or SIGSSGGPTKYADSVKG (SEQ ID NO:157), and 
 a HC CDR3 comprising the amino acid sequence LSTGELY (SEQ ID NO:146), LSIRELV (SEQ ID NO:158), LSIVDSY (SEQ ID NO:164), LSLGDSY (SEQ ID NO:170), or, LAIGDSY (SEQ ID NO:176); and 
   the LC comprises:
 a LC CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO:141), 
 a LC CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO:142), and 
 a LC CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO:143).